WASHINGTON, July 17, 2008

AIDS Vaccine Trial Scaled Back

Original Plans Were To Have Large Trial To See Effect Potential Vaccine Could Have

  •  (CBS/AP)

  • Photo Essay World AIDS Day

    Ceremonies mark day of remembrance, push prevention and treatment.

(AP)  Plans for a large-scale trial of a potential AIDS vaccine are being dropped in favor of a smaller, more focused study, the National Institutes of Health said Thursday.

The trial of the vaccine, developed by the Vaccine Research Center at the National Institute of Allergy and Infectious Disease, had been planned to include 2,400 men in the United States in a study called PAVE 100.

However, the agency said that it decided that the vaccine did not warrant a trial of this size and scope. Instead NIAID said it will plan a smaller, more focused clinical trial designed to see whether the product has a significant effect on the amount of virus in a person's blood.

If an effect is found, then additional studies, or an expansion of the study could be carried out.

NIAID said it acted after reviewing the results of the STEP trial, a study of another vaccine that was halted last fall after reports of an increased number of infections among volunteers taking part in the test.

The agency said it still considers its vaccine scientifically intriguing and sufficiently different from other vaccines to proceed with the smaller trial.


© MMVIII The Associated Press. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed.
Add a Comment
by July 18, 2008 9:02 AM EDT
The trial was halted due to the fact that the side effects would be the larger news. They will come up with a way that reduces the chance that the vaccine is another failure of synthetic drugs to cure anything.
Reply to this comment
by numberoneslr July 18, 2008 12:01 AM EDT
I think it''s good that they reviewed the trial and decided to reduce the number of people. This is one of th 3 R''s in research- refine, reduce and replace. And this is government, not Pharma-corp...(for comment #1)
Reply to this comment
by cyberus-2009 July 17, 2008 10:49 PM EDT
Pharma-corp speak for:
If it works it might impact sales of our uber-expensive aids drugs so make the trial small enough that we can poo-poo it as too small to be valid.
Reply to this comment
by barbaraf4 July 17, 2008 9:55 PM EDT
"The agency said it still considers its vaccine scientifically intriguing and sufficiently different from other vaccines to proceed with the smaller trial."
~~~~~~~~~~~~
Scientifically intriguing? This reminds me of a quote from Einstein: "Of course we don''t know what we are doing. If we did, it wouldn''t be called research".
Reply to this comment

Exclusive Webshow

Best-selling author Mitch Albom on his first nonfiction work since "Tuesdays with Morrie." Watch Now

Latest News
News in Pictures
Scroll Left Scroll Right
Connect with CBS News

Stay connected with the CBS News using your favorite social networks and online news applications: